tiprankstipranks
Dr. Reddy’s Laboratories Reports Q2 Revenue Growth
Company Announcements

Dr. Reddy’s Laboratories Reports Q2 Revenue Growth

Dr Reddy’s Laboratories (RDY) has released an update.

Don't Miss our Black Friday Offers:

Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by strong growth in global generics and emerging markets. Despite the rise in revenues, the company faced a decline in profit after tax attributable to equity holders, which fell by 15% year-over-year. The Board also approved a significant investment in its Russian subsidiary to support working capital needs, reflecting its ongoing commitment to strengthening core businesses and expanding market presence.

For further insights into RDY stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskDr. Reddy’s Receives USFDA Observations Post Inspection
TipRanks Auto-Generated NewsdeskDr. Reddy’s Gains Strong Rating Amid Robust Growth
TipRanks Auto-Generated NewsdeskDr. Reddy’s Laboratories Reports Record Quarterly Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App